文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

大建中汤(TJ-100)对结肠癌患者腹腔镜结肠切除术后胃肠道症状的影响:随机对照试验研究方案

Effect of Daikenchuto (TJ-100) on gastrointestinal symptoms following laparoscopic colectomy in patients with colon cancer: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-11-21

本研究为单中心、开放标签随机对照试验,计划纳入40例左侧结肠癌行腹腔镜结肠切除术患者(每组20例),评估大建中汤(TJ-100)对术后胃肠道症状的影响,主要终点为腹痛数字评分量表(NRS)评分、腹胀NRS评分及胃肠道生活质量指数(GIQLI),预计历时2年。

要点

  • 大建中汤(TJ-100)可能通过抑制炎症、增加肠道血流和加速肠蠕动来缓解麻痹性肠梗阻。
  • 主要终点为腹痛NRS评分、腹胀NRS评分和GIQLI生活质量评分。
  • 计划纳入40例患者(每组20例),开放标签设计,预计2年完成。

核心结论

  • 本研究旨在探究大建中汤(TJ-100)对左侧结肠癌患者腹腔镜结肠切除术后主观结局(术后生活质量)的影响,据研究者所知这是首个以此为主要终点的随机对照试验。

研究设计与样本

  • 单中心、开放标签随机对照试验,计划纳入40例左侧结肠癌行腹腔镜结肠切除术患者,每组20例,预计历时2年。

主要发现

  • 主要终点为腹痛NRS评分、腹胀NRS评分和GIQLI生活质量评分,次要终点包括术后营养状态(PNI和CONUT评分)、首次排气时间、首次排便时间、肠道气体体积、粪便性状(Bristol粪便性状量表)、每日排便次数、术后并发症(Clavien-Dindo分类)、术后住院时长以及粪便和血液代谢物。
  • 本试验将进行粪便和血液代谢物的探索性代谢组学分析,此前仅少数人体研究开展过此类分析。

临床怎么用

  • 研究旨在指导未来大规模实用性随机试验,以评估大建中汤(TJ-100)改善腹腔镜结肠切除术后生活质量的整体有效性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative paralytic ileus can be a difficult complication for both surgeons and patients. Causes and treatments have been discussed for more than two centuries, but have not yet been fully resolved. Daikenchuto (TJ-100, DKT) is a traditional Japanese herbal medicine. Recently, some beneficial mechanisms of DKT to relieve paralytic ileus have been reported. DKT can suppress inflammation, increase intestinal blood flow, and accelerate bowel movements. Therefore, we have designed a randomized controlled trial to investigate the effects of DKT on postoperative gastrointestinal symptoms following laparoscopic colectomy in patients with left-sided colon cancer at a single institution. METHODS/DESIGN: As primary endpoints, the following outcomes will be evaluated: (i) grade of abdominal pain determined using the numeric rating scale (NRS), (ii) grade of abdominal distention determined using the NRS, and (iii) quality of life determined using the Gastrointestinal Quality Life Index (GIQLI). As secondary endpoints, the following will be evaluated: (i) postoperative nutritional status (Onodera's Prognostic Nutritional Index (PNI) and the Controlling Nutritional Status score (CONUT score)), (ii) duration to initial flatus, (iii) duration to initial defecation, (iv) bowel gas volume, (v) character of stool (Bristol Stool Form Scale), (vi) defecation frequency per day, (vii) postoperative complications (Clavien-Dindo classification), (viii) length of postoperative hospital stay, and (ix) metabolites in the stool and blood. This trial is an open-label study, and needs to include 40 patients (20 patients per group) and is expected to span 2 years. DISCUSSION: To our knowledge, this is the first randomized controlled trial to investigate the effects of DKT on postoperative subjective outcomes (i.e., postoperative quality of life) following laparoscopic colectomy as primary endpoints. Exploratory metabolomics analysis of metabolites in stool and blood will be conducted in this trial, which previously has only been performed in a few human studies. The study aims to guide a future full-scale pragmatic randomized trial to assess the overall effectiveness of DKT to improve the postoperative quality of life following laparoscopic colectomy. TRIAL REGISTRATION: UMIN-CTR (Japan), UMIN000023318 . Registered on 25 July 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hoshino N, Kawada K, Hida K, et al. Effect of Daikenchuto (TJ-100) on gastrointestinal symptoms following laparoscopic colectomy in patients with colon cancer: study protocol for a randomized controlled trial. Trials. 2017. PMID: 29157273. doi:10.1186/s13063-017-2307-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。